Download the presentation here: PDF
Download the presentation here: PDF Download the presentation here: PDF
Progenics / Wyeth: Making Opioids More Tolerant • RELISTOR decreases the constipating effects $700 of opioids in patients with advanced illness who Source: EvaluatePharma are receiving palliative care. $600 • RELISTOR is the first selective peripherally $500 acting mu–opioid receptor antagonist $400 displacing opioid binding in tissues such as the USD, in millions gastrointestinal tract. $300 • RELISTOR does not diminish the central $200 analgesic effects of opioids. • $100 RELISTOR has a unique molecular structure that $0 restricts it from crossing the blood-brain barrier. • In clinical studies, RELISTOR demonstrated: 38 2007 – No clinically relevant changes in pain scores from baseline. – No central opioid withdrawal. www.wyeth.com Annual Relistor Sales Estimates 2008 2009 2010 2011 2012 2013 2014 © Defined Health, 2009 Pain Insight Briefing Oral Relistor could enable the franchise to address a potential $1B+ market opportunity in the sizable adult chronic pain population, but previous challenges warrant caution.
Adolor / Pfizer: Making Opioids More Tolerant 39 Pharmaprojects PharmaprojectsR&D R&D Pipeline Pipeline News News Feed Feed Adolor Adolorand and Pfizer Pfizer join join forces forces on on novel novel pain pain compounds compounds 7 Dec Dec 2007 2007 Pfizer Pfizer has has signed signed a deal deal with with Adolor Adolorsecuring securing exclusive exclusive worldwide worldwide rights rights to to two two novel novel compounds compounds for for pain. pain. The The deal deal grants grants Pfizer Pfizer access access to to Adolor's Adolor'sADL-5859 ADL-5859 and and ADL- ADL- 5747, 5747, both both proprietary proprietary delta delta opioid opioidreceptor receptor agonists agonists with with potential potential application application in in a wide wide range range of of inflammatory, inflammatory, neuropathic neuropathic and and acute acute pain pain conditions. conditions. There There are are three three known known opioid opioidreceptors receptors --mu, mu, kappa kappa and and delta. delta. All All current current opioid opioid analgesics analgesics exert exert their their effect effect mainly mainly on on the the mu mu variant, variant, with with no no presently-approved presently-approved compounds compounds targeted targeted specifically specifically at at the the kappa kappa or or delta delta types. types. Preclinical Preclinical work work suggests suggests that that delta-specific delta-specific agonists agonists may may exhibit exhibit superior superior analgesic analgesic properties properties to to mu mu agonists agonists whilst whilst avoiding avoiding some some of of their their common common and and undesirable undesirable side-effects. side-effects. ADL-5859 ADL-5859 is is the the most most advanced advanced compound, compound, currently currently in in Phase Phase IIa IIatrials trials in in inflammatory inflammatory pain, pain, with with more more Phase Phase II II trials trials planned planned for for 2008. 2008. An An IND IND for for ADL-5747 ADL-5747 is is pending pending and and Adolor Adoloris is planning planning to to initiate initiate clinical clinical development development in in the the first first quarter quarter of of 2008. 2008. © Defined Health, 2009 Pain Insight Briefing
- Page 1 and 2: Game Changing Plays in the Pain Mar
- Page 3 and 4: Our Disclaimer 3 The information in
- Page 5 and 6: Everyone Hurts “Pain is whatever
- Page 7 and 8: It’s A Big Market with a Few Domi
- Page 9 and 10: $ Millions But Few “Big Pharma-Si
- Page 11 and 12: Pain Historically: Drug Delivery ha
- Page 13 and 14: It’s Getting Tougher Labopharm La
- Page 15 and 16: The Risk : Reward Profile for Novel
- Page 17 and 18: Current Standard of Care for Pain
- Page 19 and 20: Leaving Plenty of Unmet Need to Be
- Page 21 and 22: In the Meantime, Let’s Teach Old
- Page 23 and 24: A Better NSAID: NicOx • Naproxcin
- Page 25 and 26: A Better NSAID: NicOx 25 Company pr
- Page 27 and 28: A Better NSAID: Pozen / AstraZeneca
- Page 29 and 30: The First-to-Market Topical NSAIDs
- Page 31 and 32: Even So, Flector is Expected To Be
- Page 33 and 34: Now We Have a Patch and a Gel Volta
- Page 35 and 36: The Need is Clear 35 © Defined Hea
- Page 37: Progenics / Wyeth: Making Opioids M
- Page 41 and 42: Like All Things CNS, It’s Not So
- Page 43 and 44: A New, and Better Opioid from J&J /
- Page 45 and 46: A New, and Better Opioid from J&J /
- Page 47 and 48: Opioid Abuse Deterrence 47 © Defin
- Page 49 and 50: King Pharmaceuticals: Making Big Be
- Page 51 and 52: But Also Significant Hurdles • Te
- Page 53 and 54: The Technologies are Not the Proble
- Page 55 and 56: The Real Issue is Risk Management
- Page 57 and 58: Fentanyl: Again, REMS is the Big Re
- Page 59 and 60: Lessons from Fentora 59 What the FD
- Page 61 and 62: For Some Mechanisms, the US Regulat
- Page 63 and 64: FAAH Pipeline 63 Compound SSR 10101
- Page 65 and 66: FAAH Pipeline KDS-4103, acquired by
- Page 67 and 68: Addressing the Big Problem 67 >50%
- Page 69 and 70: New MOA Challenges 69 NeuroDiscover
- Page 71 and 72: New MOA Challenges 71 The identific
- Page 73 and 74: TRPV1 • The transient receptor po
- Page 75 and 76: TRPV1: Target for Novel Analgesics
- Page 77 and 78: TRPV1 Antagonists: Hot … Too Hot
- Page 79 and 80: TRPV1 Antagonist Pipeline Compound
- Page 81 and 82: TRPV1 Antagonist Pipeline 81 Compou
- Page 83 and 84: TRPV3: Hopeful, But Too Early to Te
- Page 85 and 86: Good Phase III Data, An Accepted ND
- Page 87 and 88: Pfizer Pursuing Multiple Chronic Pa
Progenics / Wyeth: Making Opioids More Tolerant<br />
• RELISTOR decreases <strong>the</strong> constipating effects<br />
$700 of opioids in patients with advanced illness who<br />
Source: EvaluatePharma<br />
are receiving palliative care.<br />
$600<br />
• RELISTOR is <strong>the</strong> first selective peripherally<br />
$500<br />
acting mu–opioid receptor antagonist<br />
$400 displacing opioid binding in tissues such as <strong>the</strong><br />
USD, in millions<br />
gastrointestinal tract.<br />
$300<br />
• RELISTOR does not diminish <strong>the</strong> central<br />
$200 analgesic effects of opioids.<br />
• $100 RELISTOR has a unique molecular structure<br />
that<br />
$0<br />
restricts it from crossing <strong>the</strong> blood-brain<br />
barrier.<br />
• In clinical studies, RELISTOR demonstrated:<br />
38<br />
2007<br />
– No clinically relevant changes in pain<br />
scores from baseline.<br />
– No central opioid withdrawal.<br />
www.wyeth.com<br />
Annual Relistor Sales Estimates<br />
2008<br />
2009<br />
2010<br />
2011<br />
2012<br />
2013<br />
2014<br />
© Defined Health, 2009<br />
Pain Insight Briefing<br />
Oral Relistor could enable <strong>the</strong><br />
franchise to address a potential<br />
$1B+ market opportunity in <strong>the</strong><br />
sizable adult chronic pain<br />
population, but previous<br />
challenges warrant caution.
Change language